High immunogenicity and good tolerability of a new hepatitis A vaccine candidate
BCA Langer, A Lövestad, GG Frösner - Vaccine, 1996 - Elsevier
Immunogenicity and tolerability of a new formalin-inactivated, alum-adjuvanted whole virus
vaccine against hepatitis A (VAQTA, MSD, West Point, USA) were evaluated by immunizing
52 healthy, anti-HAV negative volunteers with a 1 ml dose. A booster dose was given 6
months later. In these young adult vaccinees [27 males and 25 females, 19–34 (mean 26)
years of age] VAQTA proved to be well tolerated and highly immunogenic. Two weeks after
administration of one vaccine dose, all but one of the recipients (98%) had anti-HAV …
vaccine against hepatitis A (VAQTA, MSD, West Point, USA) were evaluated by immunizing
52 healthy, anti-HAV negative volunteers with a 1 ml dose. A booster dose was given 6
months later. In these young adult vaccinees [27 males and 25 females, 19–34 (mean 26)
years of age] VAQTA proved to be well tolerated and highly immunogenic. Two weeks after
administration of one vaccine dose, all but one of the recipients (98%) had anti-HAV …
以上显示的是最相近的搜索结果。 查看全部搜索结果